PSI-6130

Research use only, not for human use.

A potent, specific inhibitor of HCV RNA synthesis by inhibiting the NS5B RNA polymerase (EC90=4.6 uM in replicon assay).

A potent, specific inhibitor of HCV RNA synthesis by inhibiting the NS5B RNA polymerase (EC90=4.6 uM in replicon assay); shows no anti-BVDV activity and weak antiviral activity against other flaviviruses, including West Nile virus, Dengue type 2, and yellow fever virus; has little or no cytotoxicity against various cell type.HCV Infection Discontinued.

PSI-6130 exhibits potent and specific inhibitory activity against HCV RNA replication mediated by the NS5B polymerase. Both PSI-6130 inhibit HCV GT-1b (Con1 strain) and GT-1a (H77 strain) subgenomic RNA replication, with mean EC50 values of 0.51 and 0.30 μM, respectively. PSI-6130 inhibits 40% human serum with EC50 of 0.51 μM. PSI-6130 inhibits HCV replication with a mean IC50 of 0.6 μM, PSI-6130-TP inhibits HCV replicase with a mean IC50 of 0.34 μM. PSI-6130-TP inhibits recombinant HCV Con1 NS5B on a heteropolymeric RNA template derived from the 3′-end of the negative strand of the HCV genome with an IC50 of 0.13 μM and Ki of 0.023 μM.

——

PSI6130 | R-1656 | R1656

Microbiology/Virology

HCV

HCV

Infection

HCV Infection

817204-33-4

259.2343

C10H14FN3O4

>98% (HPLC)

10 mM in DMSO

OC[C@@H]1[C@H]([C@](C)(F)[C@H](N2C(N=C(C=C2)N)=O)O1)O

Cytidine, 2'-deoxy-2'-fluoro-2'-methyl-, (2'R)-

(-20℃)

With Ice Pack

≥ 2 years